Back to Search

SHALITA JONES, MD

MD

Internal Medicine Physician

NPI: 1215032594IndividualAccepts Medicare

Specialties, Licenses & Credentials

Internal Medicine PhysicianPrimary

Internal Medicine

Code: 207R00000X

058356(GA)M4832(TX)
Hospitalist Physician

Hospitalist

Code: 208M00000X

M4832(TX)

CMS Specialties

PrimaryINTERNAL MEDICINE

Education

OTHER

Class of 2003

Research & Publications (20)

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
PMID 19204201·J Clin Oncol·2009
3-trial
Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.
PMID 16595025·Clin Breast Cancer·2006
4-observational
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
PMID 17135639·J Clin Oncol·2006
3-trial
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
PMID 16110015·J Clin Oncol·2005
3-trial
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
PMID 15865850·Clin Breast Cancer·2005
4-observational
Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.
PMID 14613022·Semin Oncol·2003
6-review
Pelvic pain and history of previous pelvic surgery.
PMID 16278726·Proc (Bayl Univ Med Cent)·2003
8-other
The influence of crystalloid and colloid replacement solutions in acute normovolemic hemodilution: a preliminary survey of hemostatic markers.
PMID 12538178·Anesth Analg·2003
3-trial
Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.
PMID 12123539·Clin Breast Cancer·2002
3-trial
A new estrogen receptor antagonist--an overview of available data.
PMID 12353819·Breast Cancer Res Treat·2002
6-review
Antiaromatase agents: evolving role in adjuvant therapy.
PMID 12020394·Clin Breast Cancer·2002
6-review
Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.
PMID 11899353·Clin Breast Cancer·2001
8-other
Surgical aspects and future developments of laparoscopy.
PMID 11244912·Anesthesiol Clin North Am·2001
6-review
Anesthesia in ambulatory minimally invasive surgery.
PMID 17016368·Curr Opin Anaesthesiol·2000
8-other
Exemestane: a novel aromatase inactivator for breast cancer.
PMID 11899645·Clin Breast Cancer·2000
6-review
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
PMID 19073509·Clin Breast Cancer·2008
4-observational
Metastatic breast cancer: the treatment challenge.
PMID 18650152·Clin Breast Cancer·2008
6-review
Considerations in treatment choice for metastatic breast cancer.
PMID 18224392·Breast Cancer·2008
8-other
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
PMID 17947724·J Clin Oncol·2007
4-observational
Direct admission to cardiology for patients hospitalized for atrial fibrillation reduces length of stay and increases guideline adherence.
PMID 16808143·Mil Med·2006
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
3600 GASTON AVE STE 550
DALLAS, TX 75246

Location

Practice Location

3600 GASTON AVE STE 550, DALLAS, TX
(214) 821-1177

Quick Facts

NPI
1215032594
Entity Type
Individual
Gender
Female
Medicare
Accepted
Specialties
3
Locations
1
Years in Practice
23
Publications
20

Are you this provider?

Claim Your Profile